ClinicalTrials.gg
TerminatedNCT01980888Updated Nov 19, 2018Results posted

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

A Phase 3 interventional study of Idelalisib and Bendamustine in Chronic Lymphocytic Leukemia, sponsored by Gilead Sciences. Terminated at 91 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
311
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
3rd of 25
311 · median 102
Started
2014
with 3 others
Phase 3
8 of 25
none open now
Registered
14th of 25
by date
Lead sponsor
19 of 25
Gilead Sciences

Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 3rd largest by enrollment, is one of 4 that started in 2014, is one of 8 in phase 3, and was the 14th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the progression-free survival in participants with previously untreated chronic lymphocytic leukemia (CLL) who would otherwise be suitable for bendamustine and rituximab treatment as standard of care.

An increased rate of deaths and serious adverse events (SAEs) among participants with front-line CLL and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Documented diagnosis of B-cell CLL, with diagnosis established according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL)
  • No prior therapy for CLL other than for disease complications
  • CLL that warrants treatment
  • Presence of measurable lymphadenopathy
  • (ECOG) performance status of ≤ 2

Key Exclusion Criteria:

  • Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
  • Known presence of myelodysplastic syndrome
  • Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of randomization
  • Ongoing liver injury
  • History of non-infectious pneumonitis
  • Ongoing inflammatory bowel disease
  • History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
  • Ongoing therapy other than corticosteroids
  • Received last dose of study drug on another therapeutic clinical trial within 30 days prior to randomization

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
311 participants (actual)

Study arms

  • Experimental
    Idelalisib+bendamustine+rituximab

    Participants will receive idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.

    Drug: Idelalisib · Drug: Bendamustine · Drug: Rituximab

  • Placebo comparator
    Placebo+bendamustine+rituximab

    Participants will receive placebo to match idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.

    Drug: Bendamustine · Drug: Rituximab · Drug: Placebo

Interventions

  • 150 mg tablet administered orally twice daily

    Also known as: Zydelig®, GS-1101, CAL-101

  • Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.

  • Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions

  • DrugPlacebo

    Placebo to match idelalisib administered orally twice daily

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival

    Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an independent review committee (IRC).

    Time frame: Up to 22 months

Secondary outcomes

  1. Overall Response Rate

    Overall response rate (ORR) is defined as the proportion of participants who achieve a confirmed complete or partial response. ORR was to be assessed by an IRC.

    Time frame: Up to 22 months

  2. Nodal Response Rate

    Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Nodal response rate was to be assessed by an IRC.

    Time frame: Up to 22 months

  3. Complete Response Rate

    Complete response rate is defined as the proportion of participants who achieve a confirmed complete response. Complete response rate was to be assessed by an IRC.

    Time frame: Up to 22 months

  4. Overall Survival

    Overall survival is defined as the interval from randomization to death from any cause. Overall survival was to be assessed by an IRC.

    Time frame: Up to 22 months

  5. Minimal Residual Disease Negativity Rate at Week 36

    Minimal residual disease (MRD) negativity rate is defined as the proportion of participants with MRD \< 10\^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation or at least 12 weeks after the last dose of rituximab or bendamustine (whichever is later) for participants receiving the final dose of rituximab after the original scheduled date. MRD negativity rate was to be assessed by an IRC.

    Time frame: Up to 22 months

07

Results

Posted Oct 11, 2017
Limitations and caveats
The study was terminated in agreement with the FDA due to urgent safety measures. Due to early study termination, the prespecified efficacy analyses were not conducted. The PFS data presented are investigator assessments rather than IRC assessments.

Participant flow

Participants were enrolled at study sites in the North America, Australia, and Europe. The first participant was screened on 05 February 2014. The last study visit occurred on 16 June 2016.

Participant flow — Overall Study
MilestoneIdelalisib+Bendamustine+RituximabPlacebo+Bendamustine+Rituximab
Started157154
Completed1321
Not completed144133
Withdrew: Study terminated by sponsor116122
Withdrew: Withdrew consent176
Withdrew: Investigator's discretion83
Withdrew: Non-compliance with study drug32

Outcome measures

PrimaryProgression-Free Survival

Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an independent review committee (IRC).

Time frame:
Up to 22 months
Reported as:
Median · months
Progression-Free Survival
monthsIdelalisib+Bendamustine+RituximabPlacebo+Bendamustine+Rituximab
Progression-Free SurvivalNA (19.3 to NA)NA (19.6 to NA)
SecondaryOverall Response Rate

Overall response rate (ORR) is defined as the proportion of participants who achieve a confirmed complete or partial response. ORR was to be assessed by an IRC.

Time frame:
Up to 22 months

No measurements were reported for this outcome.

SecondaryNodal Response Rate

Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Nodal response rate was to be assessed by an IRC.

Time frame:
Up to 22 months

No measurements were reported for this outcome.

SecondaryComplete Response Rate

Complete response rate is defined as the proportion of participants who achieve a confirmed complete response. Complete response rate was to be assessed by an IRC.

Time frame:
Up to 22 months

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival is defined as the interval from randomization to death from any cause. Overall survival was to be assessed by an IRC.

Time frame:
Up to 22 months

No measurements were reported for this outcome.

SecondaryMinimal Residual Disease Negativity Rate at Week 36

Minimal residual disease (MRD) negativity rate is defined as the proportion of participants with MRD \< 10\^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation or at least 12 weeks after the last dose of rituximab or bendamustine (whichever is later) for participants receiving the final dose of rituximab after the original scheduled date. MRD negativity rate was to be assessed by an IRC.

Time frame:
Up to 22 months

No measurements were reported for this outcome.

Adverse events

Collected over Up to 22 months plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib+Bendamustine+Rituximab—113/156 (72.4%)154/156 (98.7%)
Placebo+Bendamustine+Rituximab—68/154 (44.2%)150/154 (97.4%)
Most frequent serious events
Showing 10 of 133
Most frequent serious events
EventIdelalisib+Bendamustine+RituximabPlacebo+Bendamustine+Rituximab
Febrile neutropeniaBlood and lymphatic system disorders29/15616/154
PyrexiaGeneral disorders26/15619/154
PneumoniaInfections and infestations11/1566/154
SepsisInfections and infestations9/1562/154
AnaemiaBlood and lymphatic system disorders8/1562/154
NeutropeniaBlood and lymphatic system disorders7/1561/154
DiarrhoeaGastrointestinal disorders6/1561/154
Neutropenic sepsisInfections and infestations5/1561/154
Tumour lysis syndromeMetabolism and nutrition disorders5/1564/154
PneumonitisRespiratory, thoracic and mediastinal disorders5/1563/154
Most frequent other events
Showing 10 of 58
Most frequent other events
EventIdelalisib+Bendamustine+RituximabPlacebo+Bendamustine+Rituximab
NeutropeniaBlood and lymphatic system disorders84/15690/154
PyrexiaGeneral disorders71/15638/154
NauseaGastrointestinal disorders61/15663/154
DiarrhoeaGastrointestinal disorders63/15646/154
RashSkin and subcutaneous tissue disorders63/15634/154
FatigueGeneral disorders43/15644/154
AnaemiaBlood and lymphatic system disorders40/15629/154
VomitingGastrointestinal disorders37/15623/154
ConstipationGastrointestinal disorders26/15634/154
CoughRespiratory, thoracic and mediastinal disorders34/15629/154

Baseline characteristics

Intent-to-Treat (ITT) Analysis Set: who were randomized regardless of whether subjects received any study drug(s), or received a different regimen from the regimen to which they were randomized.

Age, Continuous
Age, Continuous(years)Idelalisib+Bendamustine+RituximabPlacebo+Bendamustine+RituximabTotal
Mean64 ± 8.763 ± 10.064 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib+Bendamustine+RituximabPlacebo+Bendamustine+RituximabTotal
Female5748105
Male100106206
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib+Bendamustine+RituximabPlacebo+Bendamustine+RituximabTotal
Asian101
Black or African American112
White152150302
Other314
Not Permitted022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib+Bendamustine+RituximabPlacebo+Bendamustine+RituximabTotal
Hispanic or Latino11213
Not Hispanic or Latino146149295
Not Permitted033
Region of Enrollment
Region of Enrollment(participants)Idelalisib+Bendamustine+RituximabPlacebo+Bendamustine+RituximabTotal
Romania415
Hungary242145
United States352560
United Kingdom71320
Spain191534
Canada11819
Czech Republic101727
Belgium336
Poland151833
Italy538
Australia151934
France459
Croatia5611
Rai Stage at Screening
Rai Stage at Screening(Participants)Idelalisib+Bendamustine+RituximabPlacebo+Bendamustine+RituximabTotal
Stage I283058
Stage II6658124
Stage III253257
Stage IV383472
IgHV Mutation
IgHV Mutation(Participants)Idelalisib+Bendamustine+RituximabPlacebo+Bendamustine+RituximabTotal
Mutated5454108
Unmutated102100202
Missing101
17p Deletion in CLL Cells
17p Deletion in CLL Cells(Participants)Idelalisib+Bendamustine+RituximabPlacebo+Bendamustine+RituximabTotal
Absent146145291
Present10919
Missing101
08

Study locations

91 sites
  • St. Jude Heritage Healthcare Virginia K. Crosson Cancer Center
    Fullerton, California 92835, United States
  • UCSD Moores Cancer Center
    La Jolla, California 92093, United States
  • Central Coast Medical Oncology
    Santa Maria, California 93454, United States
  • Georgetown University
    Washington, District of Columbia 20007, United States
  • Memorial Healthcare System
    Hollywood, Florida 33021, United States
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256, United States
  • Florida Cancer Specialists-South
    Sarasota, Florida 34236, United States
  • Franciscan Physician Network Oncology & Hematology
    Indianapolis, Indiana 46237, United States
  • Siouxland Hematology-Oncology Associates, LLP
    Sioux City, Iowa 51101, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89074, United States
  • Hematology /Oncology Associates of Northern New Jersey
    Morristown, New Jersey 07962, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • Sarah Cannon Research Institute
    Cincinnati, Ohio 45242, United States
  • Signal Point Clinical Research Center
    Middletown, Ohio 45042, United States
  • Saint Francis Hospital
    Greenville, South Carolina 29601, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Texas Oncology-Austin Midtown
    Austin, Texas 78705, United States
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84103, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • St Vincent's Hospital, Sydney
    Darlinghurst, New South Wales 2010, Australia
  • Jarrett Street Specialist Centre
    North Gosford, New South Wales 2250, Australia
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Flinders Medical Centre, Department of Haematology, Level 6
    Bedford Park, South Australia 5042, Australia
  • Ashford Cancer Centre Research
    Kurralta Park, South Australia 5037, Australia
  • Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
  • Frankston Hospital
    Frankston, Victoria 3199, Australia
  • Barwon Health, University Hospital Geelong
    Geelong, Victoria 3220, Australia
  • Z N A Stuivenberg
    Antwerpen, 2060, Belgium
  • AZ Sint-Jan AV Brugge-Oostende
    Brugge, 8000, Belgium
  • University Hospital Leuven
    Leuven, 3000, Belgium
  • Cancercare Manitoba - Maccharles Unit
    Winnipeg, Manitoba R3E 0V9, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2C9, Canada
  • Hôpital du Sacré-Coeur de Montréal
    Montréal, Quebec H4J 1C5, Canada
  • CHU de Québec - Hôpital de l'Enfant-Jésus
    Quebec City, Quebec G1J 1Z4, Canada
  • Klinicka bolnica Dubrava
    Zagreb, 10000, Croatia
  • Klinicka bolnica Merkur
    Zagreb, 10000, Croatia
  • UHC Zagreb
    Zagreb, 10000, Croatia
  • Faculty hospital Ostrava
    Ostrava-Poruba, Moravian-Silesian 70852, Czechia
  • University Hospital
    Brno, 62500, Czechia
  • Faculty Hospital Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Faculty Hospital Plzen
    Plzen, 304 60, Czechia
  • Faculty Hospital Kralovske Vinohrady
    Prague 10, 10034, Czechia
  • CHRU de Lille, Hopital Claude Huriez
    Lille, 59037, France
  • Hospital Saint-Louis
    Paris, 75010, France
  • CHU Bretonneau
    Tours, 37044, France
  • Szent Borbála Hospital
    Tatabánya, Komárom - Esztergom 2800, Hungary
  • Kaposi Mor Oktato Korhaz, Intezeti Gyogyszertar,
    Kaposvar, Somogy 7400, Hungary
  • Semmelweis University
    Budapest, 1083, Hungary
  • National Institute of Oncology
    Budapest, 1122, Hungary
  • University of Debrecen HSC Institute of internal Medicine, Department of Hematology
    Debrecen, 4032, Hungary
  • Pandy Kalman Hospital
    Gyula, 5700, Hungary
  • University Of Pecs, Medical School
    Pecs, 7624, Hungary
  • Szegedi Tudomanyegyetem AOK - Szent-Gyorgyi Albert Klinikai Kozpont, II. Belgyógyászati Klinika
    Szeged, 6725, Hungary
  • IRCCS Istituto Tumori
    Bari, Puglia 70024, Italy
  • Ospedale Oncologico Armando Businco
    Cagliari, 09121, Italy
  • Ospedale San Raffaele
    Milan, 20132, Italy
  • Azienda Ospedaliero Universitaria Policlinico di Modena
    Modena, 41124, Italy
  • AOU Maggiore della Carità
    Novara, 28100, Italy
  • Uniwersyteckie Centrum Kliniczne
    Gdańsk, Pomorskie 80-952, Poland
  • Malopolskie Centrum Medyczne s.c.
    Krakow, 30-510, Poland
  • Wojewodzki Szpital Specjalistyczny im. M. Kopernika Klinika Hematologii
    Lodz, 93-510, Poland
  • Centralny Szpital Kliniczny MSW w Warszawie Klinika Onkologii i Hematologii
    Warsaw, 02-507, Poland
  • Centrum Onkologii-Instytut Marii Sklodowskiej -Curie klinika Nowotworow Ukladu Chlonnego
    Warszawa, 02-781, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu Klinika i Katedra Hematologii,Nowotworow Krwi i Transplantacji Szpiku
    Wroclaw, 50-367, Poland
  • Dolnoslakie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku
    Wroclaw, 53-439, Poland
  • Emergency County Clinical Hospital Brasov
    Brasov, 500326, Romania
  • Spitalul Clinic Colentina
    Bucharest, 20125, Romania
  • Hospital Vall de Hebron
    Barcelona, Cataluña 08035, Spain
  • Hospital Clinic
    Barcelona, Cataluña 08036, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 8041, Spain
  • ICO, Hospitalet de Llobregat
    Barcelona, 8908, Spain
  • Hospital Universitario La Princesa
    Madrid, 28006, Spain
  • Hospital Gregorio Marañon
    Madrid, 28007, Spain
  • Hospital Universitario Ramón Y Cajal
    Madrid, 28033, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Puerta De Hierro
    Madrid, 28222, Spain
  • University College London
    London, England WC1E 6BT, United Kingdom
  • East Kent Hospitals University NHS Foundation Trust
    Canterbury, Kent CT1 3NG, United Kingdom
  • Royal Marsden NHS Trust
    Sutton, Surrey SM2 5PT, United Kingdom
  • University Hospital of Wales
    Cardiff, CF14 4XW, United Kingdom
  • Royal Liverpool & Broadgreen Univ. Hospitals NHS Trust
    Liverpool, L7 8XP, United Kingdom
  • Hammersmith Hospitals NHS Trust
    London, W12 0HS, United Kingdom
  • Oxford University Hospitals
    Oxford, OX37LE, United Kingdom
  • University Hospital Southampton NHS Trust
    Southampton, SO16 6YD, United Kingdom
  • Royal Wolverhampton Hospital NHS Trust, New Cross Hospital
    Wolverhampton, WV10 0QP, United Kingdom
09

References and documents

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2014 to primary completion in May 2016, 27 months.

Results were first posted in Oct 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2013
First posted
Nov 11, 2013
StartActual
Feb 5, 2014
Primary completionActual
May 30, 2016
CompletionActual
Jun 16, 2016
Results first posted
Oct 11, 2017
Last update
Nov 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01980888
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 11, 2013
Start date
Feb 5, 2014
Primary completion
May 30, 2016
Completion
Jun 16, 2016
Results posted
Oct 11, 2017
Last update
Nov 19, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion